Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257816 · ClinicalTrials.gov registry record · Phase 2
Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00257816 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 12 participants.
The verdict
NCT00257816, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
There will be approximately 14,000 new patients with invasive cervical cancer diagnosed in the United States in 2003 with about 4,000 deaths from this disease. This accounts for approximately 17% of all deaths due to gynecologic cancers. Radiation has been the primary treatment modality for locoregionally advanced cervical cancer. Recent trials of concomitant systemic cisplatin chemotherapy and radiation have shown high response rates (RR) with improvements in durable remissions and overall survival. Though the incidence and mortality in the U.S. dropped steadily from years 1940 to 2000, there has recently been a plateau, arresting the decline. With the routine addition of systemic Cisplatin (CDDP) chemotherapy to local regional radiation, mortality from advanced cervical cancer in the United States is expected to further decrease. However, further advances in this disease are needed.
Interventions
- DRUG Cisplatin
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257816
The ClinicalTrials.gov registry entry for NCT00257816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT00257816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257816 about?
NCT00257816 is a clinical study titled "Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma". There will be approximately 14,000 new patients with invasive cervical cancer diagnosed in the United States in 2003 with about 4,000 deaths from this disease. This accounts for approximately 17% of all deaths due to gynecologic cancers. Radiation has been the primary treatment modality for locoregi...
What is the current status of trial NCT00257816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-01. Estimated completion is 2007-12-17.
What interventions are being tested in trial NCT00257816?
The interventions under investigation include: Cisplatin (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00257816?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.